---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-042118"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:42:00.648973+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Galectin reports Q3 net loss of $0.13/sh; cash $11.5M; NAVIGATE data submitted to FDA

## Summary
- Net loss of $8.2M ($0.13/share) vs $11.2M ($0.18/share) in Q3 2024; R&D spend down to $2.6M as NAVIGATE trial ended.
- Cash and equivalents $11.5M at Sep 30; plus $10M line of credit from chairman; runway through June 2026.
- New 18-month NAVIGATE biomarker data showed belapectin reduced portal hypertension risk categories vs placebo.
- FDA data package submitted for belapectin in MASH cirrhosis; agency feedback expected by year-end 2025.

## SEC filing metadata
- accession: 0001140361-25-042118
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036125042118/0001140361-25-042118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036125042118/ny20058903x1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-042118
- JSON: https://secwatch.observer/filing/0001140361-25-042118.json
- Plain text: https://secwatch.observer/filing/0001140361-25-042118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.